ERBB2 and breast cancer: To evaluate the effects of XLLXF on HER2-positive BC cells, we treated SK-BR-3 and JIMT-1 cells with different concentrations of XLLXF (25, 50, and 100 μg/mL) alone or in combination with trastuzumab (2.7 μM).